<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">04631</article-id><article-id pub-id-type="doi">10.7554/eLife.04631</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-18599"><name><surname>Fu</surname><given-names>Wenxian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-18601"><name><surname>Farache</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-18602"><name><surname>Clardy</surname><given-names>Susan M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-18603"><name><surname>Hattori</surname><given-names>Kimie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-18604"><name><surname>Mander</surname><given-names>Palwinder</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18605"><name><surname>Lee</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-18606"><name><surname>Rioja</surname><given-names>Inmaculada</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-18607"><name><surname>Weissleder</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-18608"><name><surname>Prinjha</surname><given-names>Rab K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-15930"><name><surname>Benoist</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1136"><name><surname>Mathis</surname><given-names>Diane</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Division of Immunology, Department of Microbiology and Immunobiology</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Center for Systems Biology</institution>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Epinova DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre</institution>, <institution>GlaxoSmithKline</institution>, <addr-line><named-content content-type="city">Stevenage</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Evergrande Center for Immunologic Diseases</institution>, <institution>Harvard Medical School and Brigham and Women's Hospital</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sakaguchi</surname><given-names>Shimon</given-names></name><role>Reviewing editor</role><aff><institution>Osaka University</institution>, <country>Japan</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>dm@hms.harvard.edu</email></corresp><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Pediatrics, University of California, San Diego, La Jolla, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Rare Disease Research Unit, Pfizer, Cambridge, United States</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><elocation-id>e04631</elocation-id><history><date date-type="received"><day>05</day><month>09</month><year>2014</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Fu et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Fu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-04631-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.04631.001</object-id><p>Epigenetic modifiers are an emerging class of anti-tumor drugs, potent in multiple cancer contexts. Their effect on spontaneously developing autoimmune diseases has been little explored. We report that a short treatment with I-BET151, a small-molecule inhibitor of a family of bromodomain-containing transcriptional regulators, irreversibly suppressed development of type-1 diabetes in NOD mice. The inhibitor could prevent or clear insulitis, but had minimal influence on the transcriptomes of infiltrating and circulating T cells. Rather, it induced pancreatic macrophages to adopt an anti-inflammatory phenotype, impacting the NF-κB pathway in particular. I-BET151 also elicited regeneration of islet β-cells, inducing proliferation and expression of genes encoding transcription factors key to β-cell differentiation/function. The effect on β cells did not require T cell infiltration of the islets. Thus, treatment with I-BET151 achieves a ‘combination therapy’ currently advocated by many diabetes investigators, operating by a novel mechanism that coincidentally dampens islet inflammation and enhances β-cell regeneration.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.001">http://dx.doi.org/10.7554/eLife.04631.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.04631.002</object-id><title>eLife digest</title><p>The DNA inside a cell is often tightly wrapped around proteins to form a compact structure called chromatin. Chemical groups added to the chromatin can encourage nearby genes to either be switched on or off; and several enzymes and other proteins help to read, add, or remove these marks from the chromatin. If these chromatin modifications (or the related enzymes and proteins) are disturbed it can lead to diseases like cancer. It has also been suggested that similar changes may influence autoimmune diseases, in which the immune system attacks the body's own tissues.</p><p>Drugs that target the proteins that read, add, or remove these chromatin modifications are currently being developed to treat cancer. For example, drugs that inhibit one family of these proteins called BET have helped to treat tumors in mice that have cancers of the blood or lymph nodes. However, because these drugs target pathways involved in the immune system they may also be useful for treating autoimmune diseases.</p><p>Now Fu et al. have tested whether a BET inhibitor might be a useful treatment for type-1 diabetes. In patients with type-1 diabetes, the cells in the pancreas that produce the insulin hormone are killed off by the immune system. Without adequate levels of insulin, individuals with type-1 diabetes may experience dangerous highs and lows in their blood sugar levels and must take insulin and sometimes other medications.</p><p>Using mice that spontaneously develop type-1 diabetes when still relatively young, Fu et al. tested what would happen if the mice received a BET inhibitor for just 2 weeks early on in life. Treated mice were protected from developing type-1 diabetes for the rest of their lives. Specifically, the treatment protected the insulin-producing cells and allowed them to continue producing insulin. The drug reduced inflammation in the pancreas and increased the expression of genes that promote the regeneration of insulin-producing cells.</p><p>Diabetes researchers have been searching for drug combinations that protect the insulin-producing cells and boost their regeneration. As such, Fu et al. suggest that these findings justify further studies to see if BET inhibitors may help to treat or prevent type-1 diabetes in humans.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.002">http://dx.doi.org/10.7554/eLife.04631.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>autoimmune diabetes</kwd><kwd>bromodomain inhibitor</kwd><kwd>NF-KB</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>PO1 AI054904</award-id><principal-award-recipient><name><surname>Benoist</surname><given-names>Christophe</given-names></name><name><surname>Mathis</surname><given-names>Diane</given-names></name><name><surname>Weissleder</surname><given-names>Ralph</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004330</institution-id><institution>GlaxoSmithKline</institution></institution-wrap></funding-source><award-id>Sponsored Research Agreement</award-id><principal-award-recipient><name><surname>Benoist</surname><given-names>Christophe</given-names></name><name><surname>Mathis</surname><given-names>Diane</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006691</institution-id><institution>Harvard Medical School</institution></institution-wrap></funding-source><award-id>Schuyler Pierce Memorial Fellowship</award-id><principal-award-recipient><name><surname>Fu</surname><given-names>Wenxian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A short treatment of the NOD mouse model of type-1 diabetes with I-BET151, a small molecule bromodomain blocker, provides long-term protection from disease by inducing macrophages to adapt an anti-inflammatory tenor whilst promoting islet β cell regeneration.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Acetylation of lysine residues on histones and non-histone proteins is an important epigenetic modification of chromatin (<xref ref-type="bibr" rid="bib43">Kouzarides, 2000</xref>). Multiple ‘writers’, ‘erasers’, and ‘readers’ of this modification have been identified: histone acetyltransferases (HATs) that introduce acetyl groups, histone deacetylases (HDACs) that remove them, and bromodomain (BRD)-containing proteins that specifically recognize them. Chromatin acetylation impacts multiple fundamental cellular processes, and its dysregulation has been linked to a variety of disease states, notably various cancers (<xref ref-type="bibr" rid="bib19">Dawson and Kouzarides, 2012</xref>). Not surprisingly, then, drugs that modulate the activities of HATs or HDACs or, most recently, that block acetyl-lysine:BRD interactions are under active development in the oncology field.</p><p>BRDs, conserved from yeast to humans, are domains of approximately 110 amino-acids that recognize acetylation marks on histones (primarily H3 and H4) and certain non-histone proteins (e.g., the transcription factor, NF-κB), and serve as scaffolds for the assembly of multi-protein complexes that regulate transcription (<xref ref-type="bibr" rid="bib20">Dawson et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Prinjha et al., 2012</xref>). The BET subfamily of BRD-containing proteins (BRDs 2, 3, 4 and T) is distinguished as having tandem <bold>b</bold>romodomains followed by an ‘<bold>e</bold>xtra-<bold>t</bold>erminal’ domain. One of its members, Brd4, is critical for both ‘bookmarking’ transcribed loci post-mitotically (<xref ref-type="bibr" rid="bib81">Zhao et al., 2011</xref>) and surmounting RNA polymerase pausing downstream of transcription initiation (<xref ref-type="bibr" rid="bib37">Jang et al., 2005</xref>; <xref ref-type="bibr" rid="bib30">Hargreaves et al., 2009</xref>; <xref ref-type="bibr" rid="bib1">Anand et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Patel et al., 2013</xref>).</p><p>Recently, small-molecule inhibitors of BET proteins, for example, JQ1 and I-BET, were found to be effective inhibitors of multiple types of mouse tumors, including a NUT midline carcinoma, leukemias, lymphomas and multiple myeloma (<xref ref-type="bibr" rid="bib26">Filippakopoulos et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Dawson et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Delmore et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Zuber et al., 2011</xref>). A major, but not the unique, focus of inhibition was the Myc pathway (<xref ref-type="bibr" rid="bib22">Delmore et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Mertz et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Zuber et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Lockwood et al., 2012</xref>). In addition, BET-protein inhibitors could prevent or reverse endotoxic shock induced by systemic injection of bacterial lipopolysaccharide (LPS) (<xref ref-type="bibr" rid="bib53">Nicodeme et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Seal et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Belkina et al., 2013</xref>). The primary cellular focus of action was macrophages, and genes induced by the transcription factor NF-κB were key molecular targets (<xref ref-type="bibr" rid="bib53">Nicodeme et al., 2010</xref>; <xref ref-type="bibr" rid="bib5">Belkina et al., 2013</xref>).</p><p>Given several recent successes at transposing drugs developed for cancer therapy to the context of autoimmunity, it was logical to explore the effect of BET-protein inhibitors on autoimmune disease. We wondered how they might impact type-1 diabetes (T1D), hallmarked by specific destruction of the insulin-producing β cells of the pancreatic islets (<xref ref-type="bibr" rid="bib7">Bluestone et al., 2010</xref>). NOD mice, the ‘gold standard’ T1D model (<xref ref-type="bibr" rid="bib2">Anderson and Bluestone, 2005</xref>), spontaneously and universally develop insulitis at 4–6 weeks of age, while overt diabetes manifests in a subset of individuals beginning from 12–15 weeks, depending on the particular colony. NOD diabetes is primarily a T-cell-mediated disease, but other immune cells—such as B cells, natural killer cells, macrophages (MFs) and dendritic cells (DCs)—also play significant roles. We demonstrate that a punctual, 2-week, treatment of early- or late-stage prediabetic NOD mice with I-BET151 affords long-term protection from diabetes. Mechanistic dissection of this effect revealed important drug influences on both MFs and β cells, in particular on the NF-κB pathway. On the basis of these findings, we argue that epigenetic modifiers are an exciting, emerging option for therapeutic intervention in autoimmune diabetes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>I-BET151 protects NOD mice from development of diabetes</title><p>T1D progresses through identifiable phases, which are differentially sensitive to therapeutic intervention (<xref ref-type="bibr" rid="bib7">Bluestone et al., 2010</xref>). Therefore, we treated NOD mice with the BET-protein inhibitor, I-BET151 (GSK1210151A [<xref ref-type="bibr" rid="bib20">Dawson et al., 2011</xref>; <xref ref-type="bibr" rid="bib64">Seal et al., 2012</xref>]) according to three different protocols: from 3–5 weeks of age (incipient insulitis), from 12–14 weeks of age (established insulitis), or for 2 weeks beginning within a day after diagnosis of hyperglycemia (diabetes). Blood-glucose levels of insulitic mice were monitored until 30 weeks of age, after which animals in our colony generally do not progress to diabetes.</p><p>I-BET151 prevented diabetes development, no matter whether the treated cohort had incipient (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) or established (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) insulitis. However, the long-term protection afforded by a 2-week treatment of pre-diabetic mice was only rarely observed with recent-onset diabetic animals. Just after diagnosis, individuals were given a subcutaneous insulin implant, which lowers blood-glucose levels to the normal range within 2 days, where they remain for only about 7 days in the absence of further insulin supplementation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, upper and right panels). Normoglycemia was significantly prolonged in mice treated for 2 weeks with I-BET151; but, upon drug removal, hyperglycemia rapidly ensued in most animals (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, lower and right panels). The lack of disease reversal under these conditions suggests that β-cell destruction had proceeded to the point that dampening the autoinflammatory attack was not enough to stem hyperglycemia. However, there was prolonged protection from diabetes in a few cases, suggesting that it might prove worthwhile to explore additional treatment designs in future studies.<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.003</object-id><label>Figure 1.</label><caption><title>I-BET151 inhibits diabetes and insulitis in NOD mice.</title><p>Female NOD mice were treated with I-BET151 in DMSO (10 mg/kg daily) or just DMSO from 3–5 weeks (<bold>A</bold> and <bold>D</bold>) or 12–14 weeks (<bold>B</bold> and <bold>E</bold>) of age. (<bold>A</bold> and <bold>B</bold>) Pre-diabetic mice. Hyperglycemia was monitored until 30 weeks of age. n = 10 per group. Blue shading = treatment window. (<bold>C</bold>) Recent-onset diabetic mice. Left: Individual blood-glucose curves. An insulin pellet was implanted subcutaneously within 1 day of diabetes diagnosis (arrow). 2 days later, I-BET151 (10 mg/kg) or DMSO was administered daily for 2 weeks (shaded blue). Right: duration of normoglycemia. n = 7 or 11. (<bold>D</bold> and <bold>E</bold>) Insulitis was visualized by H&amp;E staining of paraffin sections. Left: representative histology. Middle: insulitis scores for individual mice. Grey = peri-insulitis; black = insulitis. The asterisk indicates no insulitis in any of the sections examined. Right: summary of the proportions of intact islets for individual mice. (<bold>F</bold>) Left: Total CD45<sup>+</sup> cells from the spleen (upper panel) or pancreatic islets (lower panel) from mice treated with I-BET151 or DMSO as per <xref ref-type="fig" rid="fig1">Figure 1B</xref>, and analyzed at 14 weeks. n = 6. (<bold>G</bold>) Summary data on the major immune-cell subsets as a fraction of CD45<sup>+</sup> cells, from the spleen (upper panels) or pancreas (lower panels). n = 5 or 6. p values in <bold>A</bold> and <bold>B</bold> are from Gehan-Breslow-Wilcoxon tests and in <bold>C</bold>–<bold>G</bold> are from Student's <italic>t</italic> tests.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.003">http://dx.doi.org/10.7554/eLife.04631.003</ext-link></p></caption><graphic xlink:href="elife-04631-fig1-v2.tif"/></fig></p><p>As a first step in dissecting the mechanisms of I-BET151 action, we examined its effect on insulitis. Analogous to the protocols employed above, NOD mice were treated with I-BET151 from 3–5 or 12–14 weeks of age, and their pancreas was excised for histology at 10 weeks (5 weeks being too early for quantification) or 14 weeks, respectively. Drug treatment prevented effective installation of insulitis in the young mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) and reversed established insulitis in the older animals (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>Next, we performed flow cytometric analysis of the pancreatic infiltrate. In this and subsequent mechanistic studies, we focused mainly on the 12–14-week treatment protocol because, of the successful regimens, it better models what might eventually be applied to humans. Consistent with the histological results, fewer total leukocytes (CD45<sup>+</sup> cells) were found in the pancreas, but not the spleen, of mice administered I-BET151 from 12–14 weeks of age, <italic>vis a vis</italic> vehicle-only controls (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The drop in pancreas-infiltrating cells in animals treated with the inhibitor was equally true of all populations examined (encompassing the major lymphoid and myeloid subsets) as their fractional representation within the bulk CD45<sup>+</sup> compartment appeared to be unaltered in drug- vs vehicle-treated individuals (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p></sec><sec id="s2-2"><title>BET protein inhibition has a minimal effect on T cells in NOD mice</title><p>Given that NOD diabetes is heavily dependent on CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib2">Anderson and Bluestone, 2005</xref>), and that a few recent reports have highlighted an influence of BET-protein inhibitors on the differentiation of T helper (Th) subsets in induced models of autoimmunity (<xref ref-type="bibr" rid="bib4">Bandukwala et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Mele et al., 2013</xref>), we explored the effect of I-BET151 treatment on the transcriptome of CD4<sup>+</sup> T cells isolated from relevant sites; that is, the infiltrated pancreas, draining pancreatic lymph nodes (PLNs), and control inguinal lymph nodes (ILNs). Microarray analysis of gene expression revealed surprisingly little impact of the 2-week treatment protocol on any of these populations, similar to what was observed when comparing randomly shuffled datasets (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). It is possible that the above protocol missed important effects on T cells because those remaining after prolonged drug treatment were skewed for ‘survivors’. Therefore, we also examined the transcriptomes of pancreas-infiltrating CD4<sup>+</sup> T cells at just 12, 24 or 48 hr after a single administration of I-BET151. Again, minimal, background-level, differences were observed in the gene-expression profiles of drug- and vehicle-treated mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.004</object-id><label>Figure 2.</label><caption><title>Little impact of BET-protein inhibition on CD4<sup>+</sup> T cells in NOD mice.</title><p>(<bold>A</bold>) Microarray-based transcriptional profiling of TCR<sup>+</sup>CD4<sup>+</sup> cells sorted from pancreata, pancreatic lymph nodes (PLNs) and inguinal lymph nodes (ILNs). Comparison plot of I-BET151- and DMSO-treated mice as per <xref ref-type="fig" rid="fig1">Figure 1B</xref> and analyzed at 14 weeks of age. Red, transcripts increased &gt;twofold by I-BET151; blue, transcripts &gt;twofold decreased. (<bold>B</bold>) Analogous plots of TCR<sup>+</sup>CD4<sup>+</sup> cells sorted from the pancreas of mice given a single I-BET151 (10 mg/kg) or DMSO injection, and analyzed 12, 24 or 48 hr later. (<bold>C</bold>) Th1, Th2, Th17 or Treg signatures (see ‘Materials and methods’) were superimposed on volcano plots comparing the transcriptomes of TCR<sup>+</sup>CD4<sup>+</sup> cells from the pancreas of mice treated with I-BET151 or DMSO either as per <xref ref-type="fig" rid="fig1">Figure 1B</xref> and analyzed at 14 weeks of age (upper panels) or with a single injection and analyzed 24 hr later (lower panels). Purple: over-represented signature transcripts; Green: under-represented signature transcripts. (<bold>D</bold> and <bold>E</bold>) Proportions of Treg (<bold>D</bold>) or Th17 (<bold>E</bold>) cells within the TCR<sup>+</sup>CD4<sup>+</sup> population in the pancreas of I-BET151- or DMSO-treated mice. Left, representative cytofluorometric dot plots; right, summary data. n = 4–5. p values in panel <bold>C</bold> are from the Chi-squared test (the single significant value is shown; all others were not significant) and in <bold>D</bold>–<bold>E</bold> from Student's <italic>t</italic> tests.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.004">http://dx.doi.org/10.7554/eLife.04631.004</ext-link></p></caption><graphic xlink:href="elife-04631-fig2-v2.tif"/></fig></p><p>Signature analysis, wherein we superimposed existing Th1, Th2, Th17 or Treg gene-expression signatures on p-value vs fold-change (FC) volcano plots, failed to reveal statistically significant skewing within the transcriptomes of pancreatic CD4<sup>+</sup> T cells from mice administered I-BET151 vs vehicle using either the 2-week or short-term protocols, with the possible exception of a slightly weaker Treg down-signature in I-BET151-treated animals (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Yet, we found no differences in the fraction of Tregs in the pancreatic CD4<sup>+</sup> T cell compartment, their Foxp3 expression levels or their display of CD25 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Nor, in contrast to a recent report on antigen + adjuvant induced autoimmune diseases (<xref ref-type="bibr" rid="bib50">Mele et al., 2013</xref>), could we demonstrate differences in the Th17 population—either the fraction of CD4<sup>+</sup> cells expressing IL-17A or its expression level (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). It remains possible, however, that parameters we did not assay (e.g., splicing, microRNAs) might have been different.</p></sec><sec id="s2-3"><title>I-BET151 induces a regulatory phenotype in the pancreatic macrophage population</title><p>To obtain a broader, unbiased view of the inhibitor's effect on the NOD pancreatic infiltrate, we undertook a transcriptome analysis of the bulk CD45<sup>+</sup> cell population. The 2-week and short-term treatment protocols both resulted in sets of over- and under-represented transcripts (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref> and <xref ref-type="supplementary-material" rid="SD1-data SD2-data">Supplementary files 1, 2</xref>). Interestingly, the set of decreased transcripts was evident sooner than the set of increased transcripts—the former troughing already at 12 hr, the latter still rising at 48 hr (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Taking advantage of data-sets from the Immunological Genome Project (ImmGen; <ext-link ext-link-type="uri" xlink:href="http://www.immgen.org">www.immgen.org</ext-link>), which has profiled gene expression for over 200 immunocyte populations, we found the over-represented transcripts to be indicative of myeloid-lineage cells, in particular tissue-resident MFs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). While it is possible that the changes in transcript levels reflect alterations in the relative representation of myeloid cell populations, we think rather that they resulted at least partially from gene induction or repression because they were so rapid and because only a fraction of the transcript set characteristic of any particular cell-type showed an altered level of expression. Gene-set enrichment analysis (GSEA) also highlighted transcriptional programs characteristic of MFs, the highest enrichment values being obtained for the eicosanoid, relevant nuclear receptor and complement pathways (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). All three of these pathways have been demonstrated to play a role in the resolution of inflammation, through multiple mechanisms, including the production of anti-inflammatory mediators and suppression of T cell responses (<xref ref-type="bibr" rid="bib6">Bensinger and Tontonoz, 2008</xref>; <xref ref-type="bibr" rid="bib62">Ricklin et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Serhan, 2011</xref>; <xref ref-type="bibr" rid="bib48">Lone and Tasken, 2013</xref>). Parallel analyses on the set of pancreatic CD45<sup>+</sup> cell transcripts under-represented in inhibitor-treated mice showed no striking enrichment across the ImmGen data-sets (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). And GSEA did not reveal any particular pathways to be significantly enriched.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.005</object-id><label>Figure 3.</label><caption><title>I-BET151 treatment promotes an MF-like, anti-inflammatory transcriptional program in pancreatic CD45<sup>+</sup> cells.</title><p>(<bold>A</bold> and <bold>B</bold>) A volcano plot comparing the transcriptomes of pancreatic CD45<sup>+</sup> cells from mice treated with I-BET151 or DMSO as per <xref ref-type="fig" rid="fig1">Figure 1B</xref>. Red: transcripts increased &gt;twofold; blue: transcripts decreased &gt;twofold; numbers of modulated transcripts are indicated in the corresponding color. (<bold>B</bold>) Analogous plots for mice given a single injection of I-BET151 (10 mg/kg) or DMSO only, and analyzed 12, 24 or 48 hr later. (<bold>C</bold>) Cell-type distribution of the totality of transcripts whose expression was increased &gt;twofold in panels <bold>A</bold> and <bold>B</bold> (red). Expression data for and definition of the various cell-types came from ImmGen (<ext-link ext-link-type="uri" xlink:href="http://www.Immgen.org">www.Immgen.org</ext-link>). Langerhans cells of the skin (LC.SK) have been re-positioned as per recent data (<xref ref-type="bibr" rid="bib84">Gautier et al., 2012</xref>). Expression values were row-normalized. (<bold>D</bold>) GSEA of the totality of transcripts increased in pancreatic CD45<sup>+</sup> cells of mice treated with I-BET151 (red dots in panels <bold>A</bold> and <bold>B</bold>). NES, normalized enrichment score. Representative genes showing increased expression on the right. (<bold>E</bold>) A plot analogous to that in panel <bold>C</bold> for the totality of transcripts &gt;twofold under-represented in drug-treated mice (blue dots in panels <bold>A</bold> and <bold>B</bold>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.005">http://dx.doi.org/10.7554/eLife.04631.005</ext-link></p></caption><graphic xlink:href="elife-04631-fig3-v2.tif"/></fig></p><p>We then focused specifically on the impact of I-BET151 on the NF-κB pathway in pancreatic leukocytes, with the following considerations in mind: (1) NF-κB is a critical player in many types of inflammation, exerting both pro- and anti-inflammatory influences (<xref ref-type="bibr" rid="bib74">Vallabhapurapu and Karin, 2009</xref>); (2) specifically, NF-κB has been implicated in T1D (<xref ref-type="bibr" rid="bib63">Rink et al., 2012</xref>); (3) direct binding of a BET protein, Brd4, to the RelA subunit of NF-κB has been documented (<xref ref-type="bibr" rid="bib34">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib80">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Zou et al., 2014</xref>); and (4) BET inhibitors are known to influence the NF-κB-induced transcriptional program in MFs (<xref ref-type="bibr" rid="bib53">Nicodeme et al., 2010</xref>). Interestingly, both 2-week and short-term treatment of NOD mice with I-BET151 had a dichotomous effect on the NF-κB target genes expressed by pancreatic leukocytes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, upper left panels, and <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 3</xref>; target genes extracted from [<xref ref-type="bibr" rid="bib29">Gilmore, 2006</xref>]). Pathway analysis using Ingenuity showed that, amongst these NF-κB targets, pro-inflammatory genes, particularly those encoding proteins in the tumor necrosis factor (TNF)α-induced canonical NF-κB activation pathway, were under-represented; while anti-inflammatory loci, notably those specifying molecules implicated in signaling by nuclear receptor family members, that is, the peroxisome proliferator-activated receptor (PPAR) and liver-X-receptor (LXR) families, were over-represented subsequent to I-BET151 treatment (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, upper right). These findings were confirmed by examining expression of pathway signature genes derived from the Molecular Signatures Database (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/msigdb">www.broadinstitute.org/gsea/msigdb</ext-link>): again the TNF-induced NF-κB activation pathway was down-regulated and the two nuclear receptor pathways up-regulated (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, lower panel). There were no such effects on CD45<sup>+</sup> cells isolated from the spleen or lymph nodes of the same mice.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.006</object-id><label>Figure 4.</label><caption><title>The NF-κB signaling pathway is a major focus of I-BET151's influence on NOD leukocytes.</title><p>(<bold>A</bold>) Upper panels: The inhibitor's effect on NF-κB-regulated genes—defined as per <ext-link ext-link-type="uri" xlink:href="http://www.bu.edu/nf-kb/gene-resources/target-genes">http://www.bu.edu/nf-kb/gene-resources/target-genes</ext-link>. Left, relevant transcripts from pancreatic CD45<sup>+</sup> cells of NOD mice treated long- or short-term with I-BET151 or DMSO. Red: over-represented; blue: under-represented. 2 wk: long-term, treatment as per <xref ref-type="fig" rid="fig1">Figure 1B</xref>; 48 hr: short-term, treatment with a single 10 mg/kg dose and analyzed 48 hr later. Right, signaling pathways represented by the enriched or impoverished transcripts in the data to the left, via Ingenuity pathway analysis (<ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">www.ingenuity.com</ext-link>). Lower panels: Gene sets corresponding to the TNFα-induced canonical NF-κB pathway (<xref ref-type="bibr" rid="bib86">Schaefer et al., 2009</xref>) or the PPAR and LXR pathways (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/pathway/hsa/hsa03320.html">http://www.genome.jp/kegg/pathway/hsa/hsa03320.html</ext-link>) were retrieved from the Broad Institute's Molecular Signatures Database (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/msigdb">http://www.broadinstitute.org/gsea/msigdb</ext-link>), and their expression levels in CD45<sup>+</sup> cells from pancreas of I-BET151- or vehicle-treated mice plotted. (<bold>B</bold>) 12-week-old NOD mice were injected once ip with BAY 11–7082 (10 mg/kg), sacrificed 24 hr later, and CD45<sup>+</sup> cells from the pancreas isolated and transcriptionally profiled. A volcano plot comparing treatment with BAY 11–7082 and DMSO, with genes &gt;twofold increased (in red) or decreased (in blue) by I-BET151 treatment (pooled from all time-points of <xref ref-type="fig" rid="fig3">Figure 3A,B</xref>) superimposed. (<bold>C</bold>) Effect of a single dose of 10 mg/kg BAY 11–7082 on insulitis in 12-week-old NOD mice, analyzed 24 hr after injection. Left: insulitis scores. Right: summary data for the fraction of islets with no infiltrate. Grey, peri-insulitis; Black, insulitis. (<bold>D</bold>) Suppression of in vitro T cell proliferation by cell populations isolated from the pancreas of I-BET151- or DMSO- treated mice (as per <xref ref-type="fig" rid="fig1">Figure 1B</xref>). The CD11b<sup>+</sup>CD11c<sup>−</sup> (top), CD11b<sup>−</sup>CD11c<sup>+</sup> (middle) and TCRβ<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup> (bottom) fractions of CD45<sup>+</sup> cells were sorted. To the left are representative plots of CFSE dilution; to the right are summary data quantifying division indices (see ‘Materials and methods’ for details). p values in <bold>A</bold> and <bold>B</bold> are from the chi-squared test, and in <bold>C</bold> and <bold>D</bold> are from the Student's <italic>t</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.006">http://dx.doi.org/10.7554/eLife.04631.006</ext-link></p></caption><graphic xlink:href="elife-04631-fig4-v2.tif"/></fig></p><p>We evaluated to what extent an NF-κB inhibitor could mimic the effects of I-BET151. Given its greater toxicity, a single dose of BAY 11–7082 (which blocks IκBα phosphorylation) was administered to 12-week-old NOD mice, and pancreatic CD45<sup>+</sup> cells were isolated for transcriptome analysis 24 hr later. When the sets of genes over- or under-represented in the CD45<sup>+</sup> population of I-BET151-treated mice (drawn from <xref ref-type="fig" rid="fig3">Figure 3A,B</xref>) were superimposed on a volcano plot of transcripts from CD45<sup>+</sup> cells of animals given BAY 11–7082 vs vehicle, there was an impressive correspondence, particularly for the enriched transcripts (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The match was not perfect, however, as some genes modulated by the BET-protein inhibitor were not affected by the NF-κB inhibitor and vice versa (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Perhaps not surprisingly, then, BAY 11–7082, even a single dose, could substantially clear NOD insulitis (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). (Note that it was not possible to assess the effect of this drug on diabetes development because its toxicity precluded multiple administrations.)</p><p>We performed co-culture experiments to confirm the disease-dampening potential of pancreatic MFs from mice administrated BET inhibitor. As T cells are key orchestrators of NOD diabetes (<xref ref-type="bibr" rid="bib2">Anderson and Bluestone, 2005</xref>), we examined the ability of various cell-types isolated from the pancreas of mice treated with I-BET151 or vehicle to impact an in vitro T cell proliferation assay, quantifying CFSE dilution of CD3/CD28-stimulated cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). The CD11b<sup>+</sup> population from the pancreas of vehicle-treated mice was capable of repressing T cell proliferation, but the corresponding population from mice administered I-BET151 exhibited significantly more potent suppressive activity. Co-cultured CD11c<sup>+</sup> cells did not appear to affect T cell proliferation whether isolated from control- or drug-treated mice. Treg cells isolated from the two types of mice were equally able to inhibit T cell proliferation.</p><p>It was obviously of interest to see whether I-BET151 exerted similar effects on human MFs. CD14<sup>+</sup> cells pooled from the peripheral blood of three donors were differentiated in culture; they were then incubated with I-BET151 or vehicle for 30 min, before stimulation with LPS for 4 hr; at which time, RNA was isolated for transcriptional profiling. A rank-order FC plot showed that the inhibitor greatly dampened the typical MF response to LPS (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Focusing on the NF-κB pathway: most (32/43) of the target genes inhibited in murine CD45<sup>+</sup> cells were also suppressed in human MFs (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In particular, there was suppression of secondary, over primary, LPS-response genes (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), as was previously reported for BET inhibitor treatment of mouse bone-marrow-derived MFs (<xref ref-type="bibr" rid="bib53">Nicodeme et al., 2010</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.007</object-id><label>Figure 5.</label><caption><title>Effects of I-BET151 on human monocyte-derived MFs.</title><p>Cultures of human MFs were differentiated from peripheral-blood-derived CD14<sup>+</sup> cells, pre-cultured for 30 min with I-BET151 (red bars) or just DMSO (blue bars), and stimulated for another 4 hr after the addition of LPS (100 ng/ml) or vehicle only. Microarray data from two conditions, as indicated and detailed in ‘Materials and methods’. (<bold>A</bold>) Distribution of FCs of I-BET151/DMSO for LPS-induced genes (according to the data on human monocyte-derived MFs treated with LPS or just vehicle). (<bold>B</bold>) FCs of I-BET151/DMSO of the human orthologues of the set of murine NF-κB-regulated genes illustrated in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. (<bold>C</bold>) Effects of I-BET151 on primary and secondary LPS-response genes (defined as per [<xref ref-type="bibr" rid="bib30">Hargreaves et al., 2009</xref>; <xref ref-type="bibr" rid="bib85">Ramirez-Carrozzi et al., 2009</xref>]).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.007">http://dx.doi.org/10.7554/eLife.04631.007</ext-link></p></caption><graphic xlink:href="elife-04631-fig5-v2.tif"/></fig></p></sec><sec id="s2-4"><title>BET-protein inhibition promotes regeneration of NOD β cells</title><p>We questioned whether the disease-protective effect of I-BET151 also entailed an influence on the target of the autoimmune attack, pancreatic islet β cells. As an initial approach, we compared global gene-expression profiles of flow-cytometrically purified β cells from NOD mice treated from 12–14 weeks of age with I-BET151 or vehicle. A set of about 300 transcripts was over-represented &gt;twofold in mice given the inhibitor; and about 10-fold fewer were under-represented &gt;twofold (FDR &lt; 5%) (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="supplementary-material" rid="SD4-data">Supplementary file 4</xref>). The subset of genes whose expression was increased most by the inhibitor encoded multiple members of the regenerating islet-derived (Reg) protein family, originally identified for their involvement in pancreas regeneration (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, in red) (<xref ref-type="bibr" rid="bib72">Unno et al., 1992</xref>; <xref ref-type="bibr" rid="bib35">Huszarik et al., 2010</xref>); several transcription factors (TFs) important for regeneration of β-cells (in green) (<xref ref-type="bibr" rid="bib55">Pagliuca and Melton, 2013</xref>; <xref ref-type="bibr" rid="bib68">Shih et al., 2013</xref>); and a number of proteins known to enhance insulin production (in blue) (<xref ref-type="bibr" rid="bib32">Hirayama et al., 1999</xref>; <xref ref-type="bibr" rid="bib18">Dai et al., 2006</xref>; <xref ref-type="bibr" rid="bib77">Winzell and Ahren, 2007</xref>). Interestingly, the most highly induced subset of genes also included a number of loci usually associated with neural function, encoding, for example, survival factors (<italic>Cntfr, Tox3</italic>) or promoters of synaptic development or function (<italic>Snap25, Lrrtm2, Lgi1</italic>). The top signaling pathways to emerge via GSEA were the IGF-1, IGF/mTOR, PDGF and insulin-secretion pathways (although, due to the relatively small number of genes involved, statistical significance was not reached).<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.04631.008</object-id><label>Figure 6.</label><caption><title>BET-protein inhibition promotes regeneration of islet β cells.</title><p>(<bold>A</bold>) Pancreatic β cells were cytofluorometrically sorted from mice treated with I-BET151 or DMSO as per <xref ref-type="fig" rid="fig1">Figure 1B</xref>, and microarray-based transcriptional profiling performed. Red: transcripts increased &gt;twofold by I-BET151; blue, transcripts &gt;twofold decreased. (<bold>B</bold>) NOD β-cell transcripts increased by I-BET151 ranked by FC vis-à-vis DMSO treatment. Red, regenerating islet-derived (Reg) transcripts; green, transcripts encoding transcription factors important for β-cell differentiation and function; blue, transcripts encoding proteins that enhance insulin production. (<bold>C</bold>, <bold>D</bold>, <bold>G</bold>) Cytofluorometric quantification of EdU<sup>+</sup> β cells from NOD (<bold>D</bold>) or NOD.Rag<sup>−/−</sup> (<bold>G</bold>) mice treated with I-BET151 or DMSO as in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and injected with EdU during the last 24 hr n = 5–8. Panel <bold>C</bold> shows the sorting strategy. (<bold>E</bold>) The set of red transcripts from panel <bold>A</bold> was superimposed on volcano plots comparing gene expression by β cells from NOD.Rag<sup>−/−</sup> mice treated as in <xref ref-type="fig" rid="fig1">Figure 1B</xref> with I-BET151 vs DMSO. (<bold>F</bold>) Relevant I-BET151-induced transcripts highlighted in panel <bold>B</bold> are situated on the volcano plot of panel <bold>E</bold>. (<bold>G</bold>) p values: *&lt;0.05; **&lt;0.01; *&lt;0.001—from the Student's <italic>t</italic> test for panels <bold>D</bold> and <bold>G</bold>, and from the chi-squared test for panel <bold>E</bold>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.008">http://dx.doi.org/10.7554/eLife.04631.008</ext-link></p></caption><graphic xlink:href="elife-04631-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04631.009</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Histologic analysis of β-cell proliferation in response to I-BET151 in NOD mice.</title><p>NOD mice were treated with I-BET151 or DMSO as in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. EdU was administrated during the last 24 hr. Frozen sections of pancreas were stained for insulin and EdU. Left, representative islet images; two for each condition; right, summary quantification. Small images in color are legends for insulin, EdU and DAPI, respectively. Red, EdU; green, insulin; blue, DAPI.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.009">http://dx.doi.org/10.7554/eLife.04631.009</ext-link></p></caption><graphic xlink:href="elife-04631-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04631.010</object-id><label>Figure 6—figure supplement 2.</label><caption><title>Histologic analysis of β-cell proliferation in response to I-BET151 in NOD.Rag<sup>−/−</sup> mice.</title><p>NOD.Rag<sup>−/−</sup> mice were treated with I-BET151 or DMSO as in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. EdU was administrated during the last 24 hr. Frozen sections of pancreas were stained for insulin and EdU. Left, representative islet images, two for each condition; right, summary quantification.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.010">http://dx.doi.org/10.7554/eLife.04631.010</ext-link></p></caption><graphic xlink:href="elife-04631-fig6-figsupp2-v2.tif"/></fig></fig-group></p><p>The NF-κB pathway has been implicated in the death of β-cells associated with T1D, mainly the branches downstream of inflammatory cytokine and stress stimuli (<xref ref-type="bibr" rid="bib11">Cardozo et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Cnop et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Eldor et al., 2006</xref>). Several NF-κB-dependent transcripts previously reported to be induced in β cells by the inflammatory cytokines IL-1β and IFN-γ (<xref ref-type="bibr" rid="bib11">Cardozo et al., 2001</xref>) were suppressed by I-BET151, for example, <italic>Icam1</italic>, 1.45-fold; <italic>Traf2</italic>, 1.28-fold; <italic>Fabp5</italic>, 1.23-fold. Overall, then, I-BET151 appeared to have a positive impact on β-cell regeneration and/or function.</p><p>To determine whether BET-protein inhibition induced proliferation of β cells, we treated 12-week-old NOD mice for the usual 2 weeks with I-BET151 or vehicle, injected them with 5-ethyl-2-deoxyuridine EdU 24 hr before sacrifice, and quantified EdU incorporation by β cells, delineated by their high autofluorescence and strong staining with a fluorescently conjugated exendin peptide probe (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Both the number and fraction of EdU<sup>+</sup> β cells were significantly increased in I-BET151-treated mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Analogous results were obtained using fluorescent microscopy to quantify EdU<sup>+</sup> insulin-expressing β cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>Since it has been reported that T cells in the immune infiltrate can induce β-cell replication (<xref ref-type="bibr" rid="bib69">Sreenan et al., 1999</xref>; <xref ref-type="bibr" rid="bib66">Sherry et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Dirice et al., 2013</xref>), we repeated the preceding experiments on Rag1-deficient NOD mice in order to address the possibility of a secondary effect mediated through lymphocytes. Transcriptional analysis revealed that most of the β-cell transcripts over-represented &gt;twofold by treatment of standard NOD mice with I-BET151 were also increased in inhibitor-injected NOD mice lacking T and B cells, and thereby devoid of insulitis (<xref ref-type="fig" rid="fig6">Figure 6E</xref>; and the transcripts highlighted in panel 6B are precisely positioned in panel 6F). In addition, there was a clear induction of β-cell proliferation in the absence of insulitis (<xref ref-type="fig" rid="fig6">Figure 6</xref>, panel G and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><p>We attempted to further evaluate the cell autonomy of I-BET151's effects on β cells by purifying islets from 12-week-old NOD mice and culturing them for 24 hr in the presence of inhibitor or just vehicle. No consistent differences were observed under the two culture conditions. Not surprisingly, then, a similar experiment using commercially available human islets failed to show a repeatable difference when they were cultured in the presence and absence of I-BET151. Clearly, the islet isolation/culture conditions removed or destroyed a critical factor.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The studies presented here showed that treatment of NOD mice with the epigenetic modifier, I-BET151, for a mere 2 weeks prevented the development of NOD diabetes life-long. I-BET151 was able to inhibit impending insulitis as well as clear existing islet infiltration. The drug had a dual mechanism of action: it induced the pancreatic MF population to adopt an anti-inflammatory phenotype, primarily via the NF-κB pathway, and promoted β-cell proliferation (and perhaps differentiation). These findings raise a number of intriguing questions, three of which we address here.</p><p>First, why do the mechanisms uncovered in our study appear to be so different from those proposed in the only two previous reports on the effect of BET-protein inhibitors on autoimmune disease? Bandukwala et al. found that I-BET762 (a small-molecule inhibitor similar to I-BET151) altered the differentiation of Th subsets in vitro, perturbing the typical profiles of cytokine production, and reducing the neuropathology provoked by transfer of in-vitro-differentiated Th1, but not Th17, cells reactive to a peptide of myelin oligodendrocyte glycoprotein (<xref ref-type="bibr" rid="bib4">Bandukwala et al., 2012</xref>). Unfortunately, with such transfer models, it is difficult to know how well the in vitro processes reflect in vivo events, and to distinguish subsidiary effects on cell survival and homing. Mele et al. reported that JQ1 primarily inhibited the differentiation of and cytokine production by Th17 cells, and strongly repressed collagen-induced arthritis and experimental allergic encephalomyelitis (<xref ref-type="bibr" rid="bib50">Mele et al., 2013</xref>). However, with adjuvant-induced disease models such as these, it is difficult to discriminate influences of the drug on the unfolding of autoimmune pathology vs on whatever the adjuvant is doing. Thus, the very different dual mechanism we propose for I-BET151's impact on spontaneously developing T1D in NOD mice may reflect several factors, including (but not limited to): pathogenetic differences in induced vs spontaneous autoimmune disease models; our broader analyses of immune target cell populations; and true mechanistic differences between T1D and the other diseases. As concerns the latter, it has been argued that T1D is primarily a Th1-driven disease, with little, or even a negative regulatory, influence by Th17 cells (discussed in [<xref ref-type="bibr" rid="bib44">Kriegel et al., 2011</xref>]).</p><p>Second, how does I-BET151's effect, focused on MFs and β cells, lead to life-long protection from T1D? MFs seem to play a schizophrenic role in the NOD disease. They were shown long ago to be an early participant in islet infiltration (<xref ref-type="bibr" rid="bib38">Jansen et al., 1994</xref>), and to play a critical effector role in diabetes pathogenesis, attributed primarily to the production of inflammatory cytokines and other mediators, such as iNOS (<xref ref-type="bibr" rid="bib36">Hutchings et al., 1990</xref>; <xref ref-type="bibr" rid="bib39">Jun et al., 1999a</xref>, <xref ref-type="bibr" rid="bib40">1999b</xref>; <xref ref-type="bibr" rid="bib10">Calderon et al., 2006</xref>). More recently, there has been a growing appreciation of their regulatory role in keeping diabetes in check. For example, the frequency of a small subset of pancreatic MFs expressing the complement receptor for immunoglobulin (a.k.a. CRIg) at 6–10 weeks of age determined whether or not NOD diabetes would develop months later (<xref ref-type="bibr" rid="bib28">Fu et al., 2012b</xref>), and transfer of in-vitro-differentiated M2, but not M1, MFs protected NOD mice from disease development (<xref ref-type="bibr" rid="bib57">Parsa et al., 2012</xref>).</p><p>One normally thinks of immunological tolerance as being the purview of T and B cells, but MFs seem to be playing the driving role in I-BET151's long-term immunologic impact on T1D. Chronic inflammation (as is the insulitis associated with T1D) typically entails three classes of participant: myeloid cells, in particular, tissue-resident MFs; lymphoid cells, including effector and regulatory T and B cells; and tissue-target cells, that is, islet β cells in the T1D context. The ‘flavor’ and severity of inflammation is determined by three-way interactions amongst these cellular players. One implication of this cross-talk is that a perturbation that targets primarily one of the three compartments has the potential to rebalance the dynamic process of inflammation, resetting homeostasis to a new level either beneficial or detrimental to the individual. BET-protein inhibition skewed the phenotype of pancreatic MFs towards an anti-inflammatory phenotype, whether this be at the population level through differential influx, efflux or death, or at the level of individual cells owing to changes in transcriptional programs. The ‘re-educated’ macrophages appeared to be more potent at inhibiting T cell proliferation. In addition, it is possible that MFs play some role in the I-BET151 influences on β-cell regeneration. The findings on Rag1-deficient mice ruled out the need for adaptive immune cells in the islet infiltrate for I-BET151's induction of β-cell proliferation, but MFs are not thought to be compromised in this strain. Relatedly, the lack of a consistent I-BET151 effect on cultured mouse and human islets might result from a dearth of MFs under our isolation and incubation conditions (e.g., [<xref ref-type="bibr" rid="bib45">Li et al., 2009</xref>]). Several recent publications have highlighted a role for MFs, particularly M2 cells, in promoting regeneration of β cells in diverse experimental settings (<xref ref-type="bibr" rid="bib9">Brissova et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Xiao et al., 2014</xref>), a function foretold by the reduced β-cell mass in MF-deficient <italic>Csf1</italic><sup><italic>op/op</italic></sup> mice reported a decade ago (<xref ref-type="bibr" rid="bib3">Banaei-Bouchareb et al., 2004</xref>).</p><p>Whether reflecting a cell-intrinsic or -extrinsic impact of the drug, several pro-regenerative pathways appear to be enhanced in β-cells from I-BET151-treated mice. Increased β-cell proliferation could result from up-regulation of the genes encoding Neurod1 (<xref ref-type="bibr" rid="bib42">Kojima et al., 2003</xref>), GLP-1R (<xref ref-type="bibr" rid="bib21">De Leon et al., 2003</xref>), or various of the Reg family members (<xref ref-type="bibr" rid="bib73">Unno et al., 2002</xref>; <xref ref-type="bibr" rid="bib46">Liu et al., 2008</xref>), the latter perhaps a consequence of higher IL-22R expression (<xref ref-type="bibr" rid="bib31">Hill et al., 2013</xref>) (see <xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="supplementary-material" rid="SD4-data">Supplementary file 4</xref>). Protection of β-cells from apoptosis is likely to be an important outcome of inhibiting the NF-κB pathway (<xref ref-type="bibr" rid="bib71">Takahashi et al., 2010</xref>), but could also issue from enhanced expression of other known pro-survival factors, such as Cntfr (<xref ref-type="bibr" rid="bib61">Rezende et al., 2007</xref>) and Tox3 (<xref ref-type="bibr" rid="bib24">Dittmer et al., 2011</xref>) (see <xref ref-type="fig" rid="fig4 fig6">Figures 4 and 6B</xref>). Lastly, β-cell differentiation and function should be fostered by up-regulation of genes encoding transcription factors such as Neurod1, Pdx1, Pax6, Nkx6-1 and Nkx2-2. The significant delay in re-onset of diabetes in I-BET151-treated diabetic mice suggests functionally relevant improvement in β-cell function. In brief, the striking effect of I-BET151 on T1D development in NOD mice seems to reflect the fortunate concurrence of a complex, though inter-related, set of diabetes-protective processes.</p><p>Lastly, why does a drug that inhibits BET proteins, which include general transcription factors such as Brd4, have such circumscribed effects? A 2-week I-BET151 treatment might be expected to provoke numerous side-effects, but this regimen seemed in general to be well tolerated in our studies. This conundrum has been raised in several contexts of BET-inhibitor treatment, and was recently discussed at length (<xref ref-type="bibr" rid="bib67">Shi and Vakoc, 2014</xref>). The explanation probably relates to two features of BET-protein, in particular Brd4, biology. First: Brd4 is an important element of so-called ‘super-enhancers’, defined as unusually long transcriptional enhancers that host an exceptionally high density of TFs—both cell-type-specific and general factors, including RNA polymerase-II, Mediator, p300 and Brd4 (<xref ref-type="bibr" rid="bib33">Hnisz et al., 2013</xref>). They are thought to serve as chromatin depots, collecting TFs and coordinating their delivery to transcriptional start-sites via intra-chromosome looping or inter-chromosome interactions. Super-enhancers are preferentially associated with loci that define and control the biology of particular cell-types, notably developmentally regulated and inducible genes; intriguingly, disease-associated, including T1D-associated, nucleotide polymorphisms are especially enriched in the super-enhancers of disease-relevant cell-types (<xref ref-type="bibr" rid="bib33">Hnisz et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Parker et al., 2013</xref>). Genes associated with super-enhancers show unusually high sensitivity to BET-protein inhibitors (<xref ref-type="bibr" rid="bib12">Chapuy et al., 2013</xref>; <xref ref-type="bibr" rid="bib49">Loven et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Whyte et al., 2013</xref>). Second: although the bromodomain of Brd4 binds to acetyl-lysine residues on histone-4, and I-BET151 was modeled to inhibit this interaction, it is now known to bind to a few non-histone chromosomal proteins as well, notably NF-κB, a liaison also blocked by BET-protein inhibitors (<xref ref-type="bibr" rid="bib34">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib80">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Zou et al., 2014</xref>). Abrogating specific interactions such as these, differing according to the cellular context, might be the dominant impact of BET inhibitors, a scenario that would be consistent with the similar effects we observed with I-BET151 and BAY 11–7082 treatment. Either or both of these explanations could account for the circumscribed effect of I-BET151 on NOD diabetes. Additionally, specificity might be imparted by different BET-family members or isoforms—notably both Brd2 and Brd4 are players in MF inflammatory responses (<xref ref-type="bibr" rid="bib5">Belkina et al., 2013</xref>). According to either of these explanations, higher doses might unleash a broader array of effects.</p><p>Viewed in the context of recent reports, our data point to NF-κB as a direct target of I-BET151. Traditionally, Brd4's impact on transcription has been thought to reflect its binding to histone acetyl-lysine residues, as a so-called ‘histone reader’ (<xref ref-type="bibr" rid="bib52">Muller et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Prinjha et al., 2012</xref>). Analogously, the influence of I-BET151 (and like drugs) on Brd4 function has generally been attributed to Brd4 interactions with acetylated histones (<xref ref-type="bibr" rid="bib52">Muller et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Prinjha et al., 2012</xref>). However, it is now clear that I-BET 151 directly targets Brd4's association with non-histone proteins as well. The best-studied example is NF-κB (<xref ref-type="bibr" rid="bib13">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib54">Nowak et al., 2008</xref>; <xref ref-type="bibr" rid="bib34">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib82">Zou et al., 2014</xref>). The two bromodomains of Brd4 cooperatively recognize RelA acetylated at the K310 position, and this interaction is blocked by drugs like I-BET151 and JQ1.</p><p>Of late, there has been substantial interest in treating individuals with, or at risk of, T1D with combination therapies. It would seem logical to design a combinatorial approach that targets two or more of the major players in disease—perhaps optimally, addressing elements of the innate immune system, adaptive immune system and islet target tissue. We have demonstrated that a single drug, the BRD blocker I-BET151, has a potent effect on T1D in pre-diabetic NOD mice by coincidentally influencing MFs and β cells. Recently, another drug from the cancer world, the HDAC inhibitor, vorinostat, was reported to inhibit T1D, by a seemingly different mechanism impacting a multiplicity of cell-types (<xref ref-type="bibr" rid="bib14">Christensen et al., 2014</xref>). Thus, epigenetic modulators would seem to be exciting candidates to explore in human T1D patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice and disease evaluation</title><p>NOD/Lt mice were bred under specific-pathogen–free conditions in our animal facility at the New Research Building of Harvard Medical School, cared for in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee. Relevant studies were also conducted in accordance with GSK's Policy on the Care, Welfare and Treatment of Laboratory Animals. NOD.Cg-Rag1&lt;tm1mom&gt; mice were maintained in our lab's colony at Jackson Laboratory.</p><p>For the evaluation of diabetes, mice were monitored until 30 weeks of age by measuring urine- and blood-glucose levels, as described (<xref ref-type="bibr" rid="bib41">Katz et al., 1993</xref>). Individuals with two consecutive measurements of a serum-glucose concentration above 300 mg/dl were considered diabetic. For the recent-onset cohorts: on the same day as diabetes diagnosis, individuals received a single subcutaneously implanted insulin pellet (LinShin, Toronto, Canada), which lowers the blood-glucose level to the normal range within 2 days.</p><p>For insulitis assessment, mice were euthanized, and their pancreas removed and fixed in 10% neutral-buffered formalin (Sigma–Aldrich, St. Louis, MO). Paraffin-embedded sections were cut into 6 μm sections with 150 μm between steps, and were stained with hematoxylin and eosin (H&amp;E). Insulitis was scored as described (<xref ref-type="bibr" rid="bib41">Katz et al., 1993</xref>).</p></sec><sec id="s4-2"><title>Small-molecule inhibitors</title><p>The BET-protein BRD inhibitor (I-BET151, GSK1210151A) was produced and handled as described (<xref ref-type="bibr" rid="bib20">Dawson et al., 2011</xref>). For long-term in vivo treatment, mice were ip-injected with I-BET151 dissolved in DMSO at a dose of 10 mg/kg daily for 2 weeks beginning at the designated age.</p><p>The NF-κB inhibitor (BAY 11–7082) was purchased from Sigma and dissolved in DMSO as a stock solution of 10 mg/ml. For in vivo treatment, BAY was injected ip at a dose of 10 mg/kg 24 hr before sacrificing mice for analysis.</p></sec><sec id="s4-3"><title>Flow cytometry</title><p>For immunocytes, all staining began by incubating with a mAb directed against FcγR (2.4G2; BD Pharmingen, San Diego, CA). mAbs against the following antigens were used: CD45 (30-F11), CD4 (RM4-5), CD8 (53-6.7), CD19 (6D5), CD11b (M1/70), CD11c (G418), Ly6C (AL-21), F4/80 (BM8) and IL-17A (TC11-18H10.1), all from BioLegend (San Diego, CA); and FoxP3 (FJK-16s, eBioscience, San Diego, CA).</p><p>For β cells, we followed the method described in (<xref ref-type="bibr" rid="bib45">Li et al., 2009</xref>) with modifications. Briefly, the pancreas was perfused via the common bile duct with 5 ml of a solution of collagenase P (1 mg/ml, Roche); and was then digested at 37°C for 15 min, followed by several steps of centrifugation and washing. On average, 80 islets were purified by hand-picking, and were then cultured in complete RPMI1640 medium with the fluorescent exendin-4 probe (100 nM). After 1 hr, islets were disrupted by treatment with trypsin-EDTA solution in a 37°C waterbath for 10 min. The single-cell suspensions containing β cells were analyzed by flow cytometry.</p><p>The exendin-4 probe, EP12-BTMR-X, was synthesized as previously reported (compound 17 in Table 1 of <xref ref-type="bibr" rid="bib15">Clardy et al., 2014</xref>). Briefly, an azide-functionalized BODIPY TMR-X was conjugated to exendin-4 (HGEGTFTSDLSPraQMEEEAVRLFIEWLKNGGPSSGAPPPS) using microwave-assisted copper-catalyzed azide-alkyne Huisgen cycloaddition. The conjugate was purified by HPLC and characterized by MALDI-TOF mass spectrometry and an I<sup>125</sup> binding assay.</p><p>To quantify proliferation in vivo, we ip-injected mice with 1 mg EdU 24 hr before sacrifice, and single-cell suspensions were prepared, fixed and permeabilized using the eBioscience Fixation/Permeabilization set (Cat# 00-5123, 00-5223). They were then stained using the EdU staining kit (Click-iT EdU Flow Cytometry Assay Kits; Invitrogen, Carlsbad, CA), following the users' manual.</p></sec><sec id="s4-4"><title>Microarray analysis</title><p>Pancreata were collected and digested for 30 min at 37°C with collagenase IV (1 mg/ml) and DNase I (10 U/ml). Single-cell suspensions were prepared and stained, and CD4<sup>+</sup> or CD45<sup>+</sup> cells were sorted into 500 ml TRIzol (Invitrogen) for RNA isolation. RNA was amplified in two rounds with MessageAmp aRNA (Ambion) and labeled with biotin (BioArray High Yield RNA Transcription Labeling; Enzo, Farmingdale, NY), and the resulting cRNA was hybridized to MoGene 1.0 ST (mouse) or huGene 1.0 ST (human) arrays (Affymetrix, Santa Clara, CA). Raw data were normalized by the robust multi-array average (RMA) algorithm implemented in the Expression File Creator module of the GenePattern genomic analysis platform (<xref ref-type="bibr" rid="bib60">Reich et al., 2006</xref>). For pathway analysis, GSEA was used, as described (<xref ref-type="bibr" rid="bib70">Subramanian et al., 2005</xref>). Gene-expression signatures of Th1, Th2 and Th17 cells derived from (<xref ref-type="bibr" rid="bib78">Wu et al., 2010</xref>) and (<xref ref-type="bibr" rid="bib75">Vehik and Dabelea, 2011</xref>); and signatures for Treg cells from (<xref ref-type="bibr" rid="bib27">Fu et al., 2012a</xref>).</p><p>For microarray analysis of islet β cells, NOD or NOD.Rag<sup>−/−</sup> mice were sacrificed, and collegenase P solution (0.5 mg/m) administered intrapancreatically via the bile duct. Pancreata were than digested for 20 min at 37°C. Islets were hand-picked under a stereomicroscope and a single-cell suspension prepared by treating the isolated islets with trypsin-EDTA (Life Technology, Grand Island, NY) (<xref ref-type="bibr" rid="bib8">Brennand et al., 2007</xref>). β cells were cytofluorometrically sorted on cell size and autofluorescence (<xref ref-type="bibr" rid="bib23">Dirice et al., 2013</xref>). Transcript quantification and data analysis were as above.</p></sec><sec id="s4-5"><title>In vitro suppression assays</title><p>TCRβ<sup>+</sup>CD4<sup>+</sup>CD25<sup>−</sup> naïve T cells were sorted from spleen and labeled with 10 μmol/l CFSE (Molecular Probes) in RPMI 1640 at a concentration of 10<sup>6</sup>/ml at 37°C for 20 min; then were washed, resuspended in complete culture medium (RPMI1640, 10% fetal calf serum, 2 mmol/l L-glutamine, penicillin/streptomycin, and 2-mercaptoethanol), and cultured at 1 × 10<sup>5</sup> cells/well in round-bottom, 96-well plates (Corning, Corning, NY). T cells were activated with anti-CD3/CD28 beads (at a ratio of 1:1 between cells and beads [Invitrogen]) and IL-2 (20 U/ml). Pancreatic myeloid cells from I-BET151-, or DMSO-treated mice were sorted into CD11b<sup>+</sup>CD11c<sup>low/−</sup> or CD11b<sup>low/−</sup> CD11c<sup>+</sup> fractions, and were added to cultured T cells at a ratio of myeloid:T cells of 1:4. Similarly, CD4<sup>+</sup>CD25<sup>+</sup> cells were sorted from I-BET151-, or DMSO-treated mice, and were added to cultured T cells at a ratio of 1:2. Proliferation was measured by flow-cytometric analysis of CFSE dilution, and division indices were calculated by computing the weighted fractions of all the divisions as per (<xref ref-type="bibr" rid="bib17">D'Alise et al., 2008</xref>).</p></sec><sec id="s4-6"><title>Human monocyte-derived MFs</title><p>Blood from three healthy volunteers was used to isolate buffy coats by Ficoll–Paque density gradient centrifugation. Human monocytes were purified by positive selection of CD14-expressing cells (Miltenyi Biotec, UK). They were cultured in RPMI-1640 supplemented with 5% heat-inactivated fetal calf serum (Hyclone, ThermoScientific, UK), 2 mM Glutamine (Invitrogen, UK), 100 U/ml penicillin and 100 mg/ml streptomycin containing either 5 ng/ml GM-CSF (R&amp;D Systems, UK) (condition 1) or 100 ng/ml M-CSF (R&amp;D Systems, UK) (condition 2) and cultured for 5 days to generate MFs, respectively. After 5 days, MFs were treated with fresh medium containing either 0.1% DMSO or 1 μM I-BET151 for 30 min and then stimulated with 100 ng/ml LPS (L4391, Sigma, UK), or left unstimulated. Cells were harvested at 4 hr for extracting total RNA for transcriptional profiling.</p><p>Human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents.</p></sec><sec id="s4-7"><title>Immunostaining and microscopy</title><p>For visualizing β-cell proliferation, we injected EdU (1 mg) ip 24 hr before harvesting pancreata. Paraffin sections of pancreas 6 μm in thickness were prepared. Standard procedures were used for immunostaining (<xref ref-type="bibr" rid="bib28">Fu et al., 2012b</xref>). Before the addition of primary mAbs, sections were blocked with 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA), then incubated overnight at 4°C with anti-insulin (Linco Research, St. Charles, MO), followed by FITC-AffiniPure Donkey Anti-Guinea Pig IgG (Jackson ImmunoResearch). EdU staining was performed as above. Nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole dihydrochloride). Images were acquired on an Axiovert 200M confocal microscope (Zeiss, Peabody, MA) with a xenon arc lamp in a Lambda DG-4 wavelength switcher (Sutter Instrument), and were processed with Slidebook imaging software (Intelligent Imaging, Denver, CO).</p></sec><sec id="s4-8"><title>Statistical analysis</title><p>Tests used for statistical analyses are described in the various figure legends (GraphPad software v5.0; Prism, La Jolla, CA). p values of 0.05 or less were considered to be statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank J Mohan, A Ortiz-Lopez, N Asinovski, R Cruse, K Rothamel, J LaVecchio and G Buruzala for their experimental contributions.</p></ack><sec sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>PM: GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf2"><p>KL: GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf3"><p>RKP: GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf4"><p>IR: GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf5"><p>DM: Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf6"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>WF, Designed the experiments, Performed experiments, Wrote the manuscript, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con2"><p>JF, Performed experiments, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con3"><p>KH, Performed experiments, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con4"><p>PM, Performed experiments, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con5"><p>IR, Performed experiments, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con6"><p>SMC, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con7"><p>KL, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con8"><p>RW, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con9"><p>RKP, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con10"><p>CB, Designed the experiments, Wrote the manuscript, Analyzed the data, Edited the manuscript</p></fn><fn fn-type="con" id="con11"><p>DM, Designed the experiments, Wrote the manuscript, Analyzed the data, Edited the manuscript</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: NOD/Lt mice were bred under specific-pathogen-free conditions in our animal facility at the New Research Building of Harvard Medical School, cared for in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee (#02954). Relevant studies were also conducted in accordance with GSK's Policy on the Care, Welfare and Treatment of Laboratory Animals. NOD.Cg-Rag1&lt;tm1mom&gt; mice were maintained in our lab's colony at Jackson Laboratory.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.04631.011</object-id><label>Supplementary file 1.</label><caption><p>Genes over-represented in pancreatic CD45<sup>+</sup> cells of NOD mice treated with I-BET151.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.011">http://dx.doi.org/10.7554/eLife.04631.011</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-04631-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.04631.012</object-id><label>Supplementary file 2.</label><caption><p>Genes under-represented in pancreatic CD45<sup>+</sup> cells of NOD mice treated with I-BET151.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.012">http://dx.doi.org/10.7554/eLife.04631.012</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-04631-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.04631.013</object-id><label>Supplementary file 3.</label><caption><p>Expression of NF-κB target genes in pancreatic CD45<sup>+</sup> cells of NOD mice treated with I-BET151.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.013">http://dx.doi.org/10.7554/eLife.04631.013</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-04631-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.04631.014</object-id><label>Supplementary file 4.</label><caption><p>Transcripts over-represented in β cells of NOD mice treated with I-BET151.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04631.014">http://dx.doi.org/10.7554/eLife.04631.014</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-04631-supp4-v2.xlsx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Artero</surname><given-names>PC</given-names></name><name><surname>Alaiti</surname><given-names>MA</given-names></name><name><surname>Bullard</surname><given-names>J</given-names></name><name><surname>Alazem</surname><given-names>K</given-names></name><name><surname>Margulies</surname><given-names>KB</given-names></name><name><surname>Cappola</surname><given-names>TP</given-names></name><name><surname>Lemieux</surname><given-names>M</given-names></name><name><surname>Plutzky</surname><given-names>J</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Haldar</surname><given-names>SM</given-names></name></person-group><year>2013</year><article-title>BET bromodomains mediate transcriptional pause release in heart failure</article-title><source>Cell</source><volume>154</volume><fpage>569</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.013</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><year>2005</year><article-title>The NOD mouse: a model of immune dysregulation</article-title><source>Annual Review of Immunology</source><volume>23</volume><fpage>447</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115643</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banaei-Bouchareb</surname><given-names>L</given-names></name><name><surname>Gouon-Evans</surname><given-names>V</given-names></name><name><surname>Samara-Boustani</surname><given-names>D</given-names></name><name><surname>Castellotti</surname><given-names>MC</given-names></name><name><surname>Czernichow</surname><given-names>P</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Polak</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Insulin cell mass is altered in Csf1op/Csf1op macrophage-deficient mice</article-title><source>Journal of Leukocyte Biology</source><volume>76</volume><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1189/jlb.1103591</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandukwala</surname><given-names>HS</given-names></name><name><surname>Gagnon</surname><given-names>J</given-names></name><name><surname>Togher</surname><given-names>S</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Lamperti</surname><given-names>ED</given-names></name><name><surname>Parr</surname><given-names>NJ</given-names></name><name><surname>Molesworth</surname><given-names>AM</given-names></name><name><surname>Smithers</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Witherington</surname><given-names>J</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>14532</fpage><lpage>14537</lpage><pub-id pub-id-type="doi">10.1073/pnas.1212264109</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belkina</surname><given-names>AC</given-names></name><name><surname>Nikolajczyk</surname><given-names>BS</given-names></name><name><surname>Denis</surname><given-names>GV</given-names></name></person-group><year>2013</year><article-title>BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>3670</fpage><lpage>3678</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202838</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensinger</surname><given-names>SJ</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name></person-group><year>2008</year><article-title>Integration of metabolism and inflammation by lipid-activated nuclear receptors</article-title><source>Nature</source><volume>454</volume><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nature07202</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Herold</surname><given-names>K</given-names></name><name><surname>Eisenbarth</surname><given-names>G</given-names></name></person-group><year>2010</year><article-title>Genetics, pathogenesis and clinical interventions in type 1 diabetes</article-title><source>Nature</source><volume>464</volume><fpage>1293</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1038/nature08933</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennand</surname><given-names>K</given-names></name><name><surname>Huangfu</surname><given-names>D</given-names></name><name><surname>Melton</surname><given-names>D</given-names></name></person-group><year>2007</year><article-title>All beta cells contribute equally to islet growth and maintenance</article-title><source>PLOS Biology</source><volume>5</volume><fpage>e163</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0050163</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brissova</surname><given-names>M</given-names></name><name><surname>Aamodt</surname><given-names>K</given-names></name><name><surname>Brahmachary</surname><given-names>P</given-names></name><name><surname>Prasad</surname><given-names>N</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Mellati</surname><given-names>M</given-names></name><name><surname>Shostak</surname><given-names>A</given-names></name><name><surname>Poffenberger</surname><given-names>G</given-names></name><name><surname>Aramandla</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Powers</surname><given-names>AC</given-names></name></person-group><year>2014</year><article-title>Islet microenvironment, modulated by vascular endothelial growth factor-A signaling, promotes beta cell regeneration</article-title><source>Cell Metabolism</source><volume>19</volume><fpage>498</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.02.001</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderon</surname><given-names>B</given-names></name><name><surname>Suri</surname><given-names>A</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group><year>2006</year><article-title>In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model</article-title><source>The American Journal of Pathology</source><volume>169</volume><fpage>2137</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.060539</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>AK</given-names></name><name><surname>Heimberg</surname><given-names>H</given-names></name><name><surname>Heremans</surname><given-names>Y</given-names></name><name><surname>Leeman</surname><given-names>R</given-names></name><name><surname>Kutlu</surname><given-names>B</given-names></name><name><surname>Kruhøffer</surname><given-names>M</given-names></name><name><surname>Ørntoft</surname><given-names>T</given-names></name><name><surname>Eizirik</surname><given-names>DL</given-names></name></person-group><year>2001</year><article-title>A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>48879</fpage><lpage>48886</lpage><pub-id pub-id-type="doi">10.1074/jbc.M108658200</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapuy</surname><given-names>B</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Roemer</surname><given-names>MG</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Sun</surname><given-names>HH</given-names></name><name><surname>Yeda</surname><given-names>KT</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Reichert</surname><given-names>E</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Shipp</surname><given-names>MA</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><year>2013</year><article-title>Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma</article-title><source>Cancer Cell</source><volume>24</volume><fpage>777</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.11.003</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LF</given-names></name><name><surname>Williams</surname><given-names>SA</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Duerr</surname><given-names>JM</given-names></name><name><surname>Buckbinder</surname><given-names>L</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year>2005</year><article-title>NF-kappaB RelA phosphorylation regulates RelA acetylation</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>7966</fpage><lpage>7975</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.18.7966-7975.2005</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>DP</given-names></name><name><surname>Gysemans</surname><given-names>C</given-names></name><name><surname>Lundh</surname><given-names>M</given-names></name><name><surname>Dahllof</surname><given-names>MS</given-names></name><name><surname>Noesgaard</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>SF</given-names></name><name><surname>Mandrup</surname><given-names>S</given-names></name><name><surname>Birkbak</surname><given-names>N</given-names></name><name><surname>Workman</surname><given-names>CT</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name><name><surname>Blaabjerg</surname><given-names>L</given-names></name><name><surname>Monzani</surname><given-names>V</given-names></name><name><surname>Fossati</surname><given-names>G</given-names></name><name><surname>Mascagni</surname><given-names>P</given-names></name><name><surname>Paraskevas</surname><given-names>S</given-names></name><name><surname>Aikin</surname><given-names>RA</given-names></name><name><surname>Billestrup</surname><given-names>N</given-names></name><name><surname>Grunnet</surname><given-names>LG</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Mandrup-Poulsen</surname><given-names>T</given-names></name></person-group><year>2014</year><article-title>Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and beta-cell protection</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>111</volume><fpage>1055</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320850111</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clardy</surname><given-names>SM</given-names></name><name><surname>Keliher</surname><given-names>EJ</given-names></name><name><surname>Mohan</surname><given-names>JF</given-names></name><name><surname>Sebas</surname><given-names>M</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><year>2014</year><article-title>Fluorescent exendin-4 derivatives for pancreatic beta-cell analysis</article-title><source>Bioconjugate Chemistry</source><volume>25</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1021/bc4005014</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cnop</surname><given-names>M</given-names></name><name><surname>Welsh</surname><given-names>N</given-names></name><name><surname>Jonas</surname><given-names>JC</given-names></name><name><surname>Jörns</surname><given-names>A</given-names></name><name><surname>Lenzen</surname><given-names>S</given-names></name><name><surname>Eizirik</surname><given-names>DL</given-names></name></person-group><year>2005</year><article-title>Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities</article-title><source>Diabetes</source><volume>54</volume><supplement>Suppl 2</supplement><fpage>S97</fpage><lpage>S107</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.suppl_2.S97</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Alise</surname><given-names>AM</given-names></name><name><surname>Auyeung</surname><given-names>V</given-names></name><name><surname>Feuerer</surname><given-names>M</given-names></name><name><surname>Nishio</surname><given-names>J</given-names></name><name><surname>Fontenot</surname><given-names>J</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>105</volume><fpage>19857</fpage><lpage>19862</lpage><pub-id pub-id-type="doi">10.1073/pnas.0810713105</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>FF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gaisano</surname><given-names>HY</given-names></name><name><surname>Braunewell</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>CB</given-names></name><name><surname>Wheeler</surname><given-names>MB</given-names></name></person-group><year>2006</year><article-title>The neuronal Ca2+ sensor protein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>21942</fpage><lpage>21953</lpage><pub-id pub-id-type="doi">10.1074/jbc.M512924200</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2012</year><article-title>Cancer epigenetics: from mechanism to therapy</article-title><source>Cell</source><volume>150</volume><fpage>12</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.013</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>WI</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Huthmacher</surname><given-names>C</given-names></name><name><surname>Gudgin</surname><given-names>E</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>EJ</given-names></name><name><surname>Soden</surname><given-names>PE</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Doehner</surname><given-names>K</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2011</year><article-title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nature10509</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De León</surname><given-names>DD</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Madani</surname><given-names>R</given-names></name><name><surname>Ahima</surname><given-names>RS</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Stoffers</surname><given-names>DA</given-names></name></person-group><year>2003</year><article-title>Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy</article-title><source>Diabetes</source><volume>52</volume><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.2.365</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name></person-group><year>2011</year><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirice</surname><given-names>E</given-names></name><name><surname>Kahraman</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>El</surname><given-names>OA</given-names></name><name><surname>De Jesus</surname><given-names>DF</given-names></name><name><surname>Teo</surname><given-names>AK</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Kawamori</surname><given-names>D</given-names></name><name><surname>Gaglia</surname><given-names>JL</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Kulkarni</surname><given-names>RN</given-names></name></person-group><year>2013</year><article-title>Soluble factors secreted by T-cells promote beta-cell proliferation</article-title><source>Diabetes</source><volume>63</volume><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2337/db13-0204</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>S</given-names></name><name><surname>Kovacs</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>SH</given-names></name><name><surname>Siszler</surname><given-names>G</given-names></name><name><surname>Kögl</surname><given-names>M</given-names></name><name><surname>Summer</surname><given-names>H</given-names></name><name><surname>Geerts</surname><given-names>A</given-names></name><name><surname>Golz</surname><given-names>S</given-names></name><name><surname>Shioda</surname><given-names>T</given-names></name><name><surname>Methner</surname><given-names>A</given-names></name></person-group><year>2011</year><article-title>TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex</article-title><source>Journal of Cell Science</source><volume>124</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1242/jcs.068759</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldor</surname><given-names>R</given-names></name><name><surname>Yeffet</surname><given-names>A</given-names></name><name><surname>Baum</surname><given-names>K</given-names></name><name><surname>Doviner</surname><given-names>V</given-names></name><name><surname>Amar</surname><given-names>D</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name><name><surname>Christofori</surname><given-names>G</given-names></name><name><surname>Peled</surname><given-names>A</given-names></name><name><surname>Carel</surname><given-names>JC</given-names></name><name><surname>Boitard</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>T</given-names></name><name><surname>Serup</surname><given-names>P</given-names></name><name><surname>Eizirik</surname><given-names>DL</given-names></name><name><surname>Melloul</surname><given-names>D</given-names></name></person-group><year>2006</year><article-title>Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>103</volume><fpage>5072</fpage><lpage>5077</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508166103</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Picaud</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>WB</given-names></name><name><surname>Fedorov</surname><given-names>O</given-names></name><name><surname>Morse</surname><given-names>EM</given-names></name><name><surname>Keates</surname><given-names>T</given-names></name><name><surname>Hickman</surname><given-names>TT</given-names></name><name><surname>Felletar</surname><given-names>I</given-names></name><name><surname>Philpott</surname><given-names>M</given-names></name><name><surname>Munro</surname><given-names>S</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Christie</surname><given-names>AL</given-names></name><name><surname>West</surname><given-names>N</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Heightman</surname><given-names>TD</given-names></name><name><surname>La Thangue</surname><given-names>N</given-names></name><name><surname>French</surname><given-names>CA</given-names></name><name><surname>Wiest</surname><given-names>O</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><year>2010</year><article-title>Selective inhibition of BET bromodomains</article-title><source>Nature</source><volume>468</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1038/nature09504</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Ergun</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Haxhinasto</surname><given-names>S</given-names></name><name><surname>Fassett</surname><given-names>MS</given-names></name><name><surname>Gazit</surname><given-names>R</given-names></name><name><surname>Adoro</surname><given-names>S</given-names></name><name><surname>Glimcher</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Kastner</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><year>2012a</year><article-title>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells</article-title><source>Nature Immunology</source><volume>13</volume><fpage>972</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1038/ni.2420</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Wojtkiewicz</surname><given-names>G</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year>2012b</year><article-title>Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging</article-title><source>Nature Immunology</source><volume>13</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/ni.2233</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Ivanov</surname><given-names>S</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Elpek</surname><given-names>KG</given-names></name><name><surname>Gordonov</surname><given-names>S</given-names></name><name><surname>Mazloom</surname><given-names>AR</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>WJ</given-names></name><name><surname>Hansen</surname><given-names>TH</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><collab>Immunological Genome Consortium</collab></person-group><year>2012</year><article-title>Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages</article-title><source>Nature Immunology</source><volume>13</volume><fpage>1118</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1038/ni.2419</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmore</surname><given-names>TD</given-names></name></person-group><year>2006</year><article-title>Introduction to NF-kappaB: players, pathways, perspectives</article-title><source>Oncogene</source><volume>25</volume><fpage>6680</fpage><lpage>6684</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209954</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hargreaves</surname><given-names>DC</given-names></name><name><surname>Horng</surname><given-names>T</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year>2009</year><article-title>Control of inducible gene expression by signal-dependent transcriptional elongation</article-title><source>Cell</source><volume>138</volume><fpage>129</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.05.047</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>T</given-names></name><name><surname>Krougly</surname><given-names>O</given-names></name><name><surname>Nikkoopour</surname><given-names>E</given-names></name><name><surname>Bellmore</surname><given-names>S</given-names></name><name><surname>Lee-Chan</surname><given-names>E</given-names></name><name><surname>Fouser</surname><given-names>LA</given-names></name><name><surname>Hill</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name></person-group><year>2013</year><article-title>The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative <italic>Reg</italic> genes</article-title><source>Cell Regen</source><volume>2</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/2045-9769-2-2</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>I</given-names></name><name><surname>Tamemoto</surname><given-names>H</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><name><surname>Nagamachi</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name></person-group><year>1999</year><article-title>Insulin receptor-related receptor is expressed in pancreatic beta-cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and -2</article-title><source>Diabetes</source><volume>48</volume><fpage>1237</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.2337/diabetes.48.6.1237</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hnisz</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>BJ</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Saint-Andre</surname><given-names>V</given-names></name><name><surname>Sigova</surname><given-names>AA</given-names></name><name><surname>Hoke</surname><given-names>HA</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>2013</year><article-title>Super-enhancers in the control of cell identity and disease</article-title><source>Cell</source><volume>155</volume><fpage>934</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.053</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>XD</given-names></name><name><surname>Zhou</surname><given-names>MM</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>LF</given-names></name></person-group><year>2009</year><article-title>Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA</article-title><source>Molecular and Cellular Biology</source><volume>29</volume><fpage>1375</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1128/MCB.01365-08</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huszarik</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>B</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Nikoopour</surname><given-names>E</given-names></name><name><surname>Krougly</surname><given-names>O</given-names></name><name><surname>Lee-Chan</surname><given-names>E</given-names></name><name><surname>Qin</surname><given-names>HY</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Gurr</surname><given-names>WK</given-names></name><name><surname>Hill</surname><given-names>DJ</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name></person-group><year>2010</year><article-title>Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice</article-title><source>The Journal of Immunology</source><volume>185</volume><fpage>5120</fpage><lpage>5129</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001596</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>P</given-names></name><name><surname>Rosen</surname><given-names>H</given-names></name><name><surname>O'Reilly</surname><given-names>L</given-names></name><name><surname>Simpson</surname><given-names>E</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Cooke</surname><given-names>A</given-names></name></person-group><year>1990</year><article-title>Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages</article-title><source>Nature</source><volume>348</volume><fpage>639</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/348639a0</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>MK</given-names></name><name><surname>Mochizuki</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Jeong</surname><given-names>HS</given-names></name><name><surname>Brady</surname><given-names>JN</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year>2005</year><article-title>The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription</article-title><source>Molecular Cell</source><volume>19</volume><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.06.027</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>A</given-names></name><name><surname>Homo-Delarche</surname><given-names>F</given-names></name><name><surname>Hooijkaas</surname><given-names>H</given-names></name><name><surname>Leenen</surname><given-names>PJ</given-names></name><name><surname>Dardenne</surname><given-names>M</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name></person-group><year>1994</year><article-title>Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice</article-title><source>Diabetes</source><volume>43</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.2337/diab.43.5.667</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>HS</given-names></name><name><surname>Santamaria</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Yoon</surname><given-names>JW</given-names></name></person-group><year>1999a</year><article-title>Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice</article-title><source>Diabetes</source><volume>48</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.2337/diabetes.48.1.34</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>HS</given-names></name><name><surname>Yoon</surname><given-names>CS</given-names></name><name><surname>Zbytnuik</surname><given-names>L</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Yoon</surname><given-names>JW</given-names></name></person-group><year>1999b</year><article-title>The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice</article-title><source>The Journal of Experimental Medicine</source><volume>189</volume><fpage>347</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1084/jem.189.2.347</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Haskins</surname><given-names>K</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year>1993</year><article-title>Following a diabetogenic T cell from genesis through pathogenesis</article-title><source>Cell</source><volume>74</volume><fpage>1089</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90730-E</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Fujimiya</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Younan</surname><given-names>P</given-names></name><name><surname>Imaeda</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name></person-group><year>2003</year><article-title>NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice</article-title><source>Nature Medicine</source><volume>9</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1038/nm867</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2000</year><article-title>Acetylation: a regulatory modification to rival phosphorylation?</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>1176</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.6.1176</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriegel</surname><given-names>MA</given-names></name><name><surname>Sefik</surname><given-names>E</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year>2011</year><article-title>Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>11548</fpage><lpage>11553</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108924108</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>DS</given-names></name><name><surname>Yuan</surname><given-names>YH</given-names></name><name><surname>Tu</surname><given-names>HJ</given-names></name><name><surname>Liang</surname><given-names>QL</given-names></name><name><surname>Dai</surname><given-names>LJ</given-names></name></person-group><year>2009</year><article-title>A protocol for islet isolation from mouse pancreas</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1649</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.150</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name></person-group><year>2008</year><article-title>Possible roles of reg family proteins in pancreatic islet cell growth</article-title><source>Endocrine, Metabolic &amp; Immune Disorders Drug Targets</source><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2174/187153008783928361</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><year>2012</year><article-title>Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>19408</fpage><lpage>19413</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216363109</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lone</surname><given-names>AM</given-names></name><name><surname>Taskén</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>Proinflammatory and immunoregulatory roles of eicosanoids in T cells</article-title><source>Frontiers in Immunology</source><volume>4</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00130</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loven</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>HA</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>2013</year><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title><source>Cell</source><volume>153</volume><fpage>320</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.036</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Salmeron</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>HR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Lora</surname><given-names>JM</given-names></name></person-group><year>2013</year><article-title>BET bromodomain inhibition suppresses TH17-mediated pathology</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>2181</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1084/jem.20130376</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>JA</given-names></name><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sims</surname><given-names>RJ</given-names><suffix>III</suffix></name></person-group><year>2011</year><article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108190108</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year>2011</year><article-title>Bromodomains as therapeutic targets</article-title><source>Expert Reviews in Molecular Medicine</source><volume>13</volume><fpage>e29</fpage><pub-id pub-id-type="doi">10.1017/S1462399411001992</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicodeme</surname><given-names>E</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Schaefer</surname><given-names>U</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Chandwani</surname><given-names>R</given-names></name><name><surname>Marazzi</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Coste</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Kirilovsky</surname><given-names>J</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Lora</surname><given-names>JM</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Suppression of inflammation by a synthetic histone mimic</article-title><source>Nature</source><volume>468</volume><fpage>1119</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1038/nature09589</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>DE</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Jamaluddin</surname><given-names>M</given-names></name><name><surname>Boldogh</surname><given-names>I</given-names></name><name><surname>Vergara</surname><given-names>LA</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Brasier</surname><given-names>AR</given-names></name></person-group><year>2008</year><article-title>RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>3623</fpage><lpage>3638</lpage><pub-id pub-id-type="doi">10.1128/MCB.01152-07</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliuca</surname><given-names>FW</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group><year>2013</year><article-title>How to make a functional beta-cell</article-title><source>Development</source><volume>140</volume><fpage>2472</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1242/dev.093187</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>SC</given-names></name><name><surname>Stitzel</surname><given-names>ML</given-names></name><name><surname>Taylor</surname><given-names>DL</given-names></name><name><surname>Orozco</surname><given-names>JM</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Akiyama</surname><given-names>JA</given-names></name><name><surname>van Bueren</surname><given-names>KL</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name>, <collab>NISC Comparative Sequencing Program</collab><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Visel</surname><given-names>A</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Collins FS</surname></name>, <collab>National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program Authors</collab>, <collab>NISC Comparative Sequencing Program Authors</collab></person-group><year>2013</year><article-title>Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>110</volume><fpage>17921</fpage><lpage>17926</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317023110</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsa</surname><given-names>R</given-names></name><name><surname>Andresen</surname><given-names>P</given-names></name><name><surname>Gillett</surname><given-names>A</given-names></name><name><surname>Mia</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>XM</given-names></name><name><surname>Mayans</surname><given-names>S</given-names></name><name><surname>Holmberg</surname><given-names>D</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name></person-group><year>2012</year><article-title>Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice</article-title><source>Diabetes</source><volume>61</volume><fpage>2881</fpage><lpage>2892</lpage><pub-id pub-id-type="doi">10.2337/db11-1635</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>MC</given-names></name><name><surname>Debrosse</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Huynh</surname><given-names>W</given-names></name><name><surname>Sarai</surname><given-names>N</given-names></name><name><surname>Heightman</surname><given-names>TD</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>2497</fpage><lpage>2507</lpage><pub-id pub-id-type="doi">10.1128/MCB.01180-12</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Witherington</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name></person-group><year>2012</year><article-title>Place your BETs: the therapeutic potential of bromodomains</article-title><source>Trends in Pharmacological Sciences</source><volume>33</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.12.002</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Carrozzi</surname><given-names>VR</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>Bhatt</surname><given-names>DM</given-names></name><name><surname>Cheng</surname><given-names>CS</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Doty</surname><given-names>KR</given-names></name><name><surname>Black</surname><given-names>JC</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>M</given-names></name><name><surname>Smale</surname><given-names>ST</given-names></name></person-group><year>2009</year><article-title>A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling</article-title><source>Cell</source><volume>138</volume><fpage>114</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.020</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>J</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year>2006</year><article-title>GenePattern 2.0</article-title><source>Nature Genetics</source><volume>38</volume><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/ng0506-500</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>LF</given-names></name><name><surname>Stoppiglia</surname><given-names>LF</given-names></name><name><surname>Souza</surname><given-names>KL</given-names></name><name><surname>Negro</surname><given-names>A</given-names></name><name><surname>Langone</surname><given-names>F</given-names></name><name><surname>Boschero</surname><given-names>AC</given-names></name></person-group><year>2007</year><article-title>Ciliary neurotrophic factor promotes survival of neonatal rat islets via the BCL-2 anti-apoptotic pathway</article-title><source>The Journal of Endocrinology</source><volume>195</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1677/JOE-07-0016</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricklin</surname><given-names>D</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group><year>2010</year><article-title>Complement: a key system for immune surveillance and homeostasis</article-title><source>Nature Immunology</source><volume>11</volume><fpage>785</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/ni.1923</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rink</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kaufman</surname><given-names>DB</given-names></name></person-group><year>2012</year><article-title>Conditional and specific inhibition of NF-kappaB in mouse pancreatic beta cells prevents cytokine-induced deleterious effects and improves islet survival posttransplant</article-title><source>Surgery</source><volume>151</volume><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2011.07.011</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>CF</given-names></name><name><surname>Anthony</surname><given-names>K</given-names></name><name><surname>Krupa</surname><given-names>S</given-names></name><name><surname>Buchoff</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Hannay</surname><given-names>T</given-names></name><name><surname>Buetow</surname><given-names>KH</given-names></name></person-group><year>2009</year><article-title>PID: the Pathway Interaction Database</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>D674</fpage><lpage>D679</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn653</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>J</given-names></name><name><surname>Lamotte</surname><given-names>Y</given-names></name><name><surname>Donche</surname><given-names>F</given-names></name><name><surname>Bouillot</surname><given-names>A</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Gellibert</surname><given-names>F</given-names></name><name><surname>Nicodeme</surname><given-names>E</given-names></name><name><surname>Krysa</surname><given-names>G</given-names></name><name><surname>Kirilovsky</surname><given-names>J</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>McCleary</surname><given-names>S</given-names></name><name><surname>Rioja</surname><given-names>I</given-names></name><name><surname>Bamborough</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Gordon</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>AL</given-names></name><name><surname>Cutler</surname><given-names>L</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>DM</given-names></name><name><surname>Witherington</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name></person-group><year>2012</year><article-title>Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>22</volume><fpage>2968</fpage><lpage>2972</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.02.041</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>CN</given-names></name></person-group><year>2011</year><article-title>The resolution of inflammation: the devil in the flask and in the details</article-title><source>FASEB Journal</source><volume>25</volume><fpage>1441</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1096/fj.11-0502ufm</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>NA</given-names></name><name><surname>Kushner</surname><given-names>JA</given-names></name><name><surname>Glandt</surname><given-names>M</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Brillantes</surname><given-names>AM</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name></person-group><year>2006</year><article-title>Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes</article-title><source>Diabetes</source><volume>55</volume><fpage>3238</fpage><lpage>3245</lpage><pub-id pub-id-type="doi">10.2337/db05-1034</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name></person-group><year>2014</year><article-title>The mechanisms behind the therapeutic activity of BET bromodomain inhibition</article-title><source>Molecular Cell</source><volume>54</volume><fpage>728</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.05.016</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>HP</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Sander</surname><given-names>M</given-names></name></person-group><year>2013</year><article-title>Pancreas organogenesis: from lineage determination to morphogenesis</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>29</volume><fpage>81</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-101512-122405</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreenan</surname><given-names>S</given-names></name><name><surname>Pick</surname><given-names>AJ</given-names></name><name><surname>Levisetti</surname><given-names>M</given-names></name><name><surname>Baldwin</surname><given-names>AC</given-names></name><name><surname>Pugh</surname><given-names>W</given-names></name><name><surname>Polonsky</surname><given-names>KS</given-names></name></person-group><year>1999</year><article-title>Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse</article-title><source>Diabetes</source><volume>48</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.2337/diabetes.48.5.989</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year>2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Kamachi</surname><given-names>H</given-names></name><name><surname>Tsuruga</surname><given-names>Y</given-names></name><name><surname>Kasai</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Umezawa</surname><given-names>K</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name></person-group><year>2010</year><article-title>Donor pretreatment with DHMEQ improves islet transplantation</article-title><source>The Journal of Surgical Research</source><volume>163</volume><fpage>e23</fpage><lpage>e34</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2010.04.044</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unno</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Miyashita</surname><given-names>H</given-names></name><name><surname>Moriizumi</surname><given-names>S</given-names></name><name><surname>Teraoka</surname><given-names>H</given-names></name><name><surname>Yonekura</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name></person-group><year>1992</year><article-title>Islet beta-cell regeneration and reg genes</article-title><source>Advances in Experimental Medicine and Biology</source><volume>321</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/978-1-4615-3448-8_8</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unno</surname><given-names>M</given-names></name><name><surname>Nata</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>N</given-names></name><name><surname>Narushima</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Takasawa</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name></person-group><year>2002</year><article-title>Production and characterization of Reg knockout mice: reduced proliferation of pancreatic beta-cells in Reg knockout mice</article-title><source>Diabetes</source><volume>51</volume><supplement>Suppl 3</supplement><fpage>S478</fpage><lpage>S483</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S478</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallabhapurapu</surname><given-names>S</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>Regulation and function of NF-kappaB transcription factors in the immune system</article-title><source>Annual Review of Immunology</source><volume>27</volume><fpage>693</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132641</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name></person-group><year>2011</year><article-title>The changing epidemiology of type 1 diabetes: why is it going through the roof?</article-title><source>Diabetes/Metabolism Research and Reviews</source><volume>27</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1141</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whyte</surname><given-names>WA</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Hnisz</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>BJ</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Kagey</surname><given-names>MH</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>2013</year><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title><source>Cell</source><volume>153</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.035</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winzell</surname><given-names>MS</given-names></name><name><surname>Ahren</surname><given-names>B</given-names></name></person-group><year>2007</year><article-title>Role of VIP and PACAP in islet function</article-title><source>Peptides</source><volume>28</volume><fpage>1805</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2007.04.024</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Ivanov</surname><given-names>II</given-names></name><name><surname>Darce</surname><given-names>J</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Umesaki</surname><given-names>Y</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><year>2010</year><article-title>Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells</article-title><source>Immunity</source><volume>32</volume><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.06.001</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Gaffar</surname><given-names>I</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Wiersch</surname><given-names>J</given-names></name><name><surname>Fischbach</surname><given-names>S</given-names></name><name><surname>Peirish</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>El-Gohary</surname><given-names>Y</given-names></name><name><surname>Prasadan</surname><given-names>K</given-names></name><name><surname>Shiota</surname><given-names>C</given-names></name><name><surname>Gittes</surname><given-names>GK</given-names></name></person-group><year>2014</year><article-title>M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>111</volume><fpage>E1211</fpage><lpage>E1220</lpage><pub-id pub-id-type="doi">10.1073/pnas.1321347111</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Plotnikov</surname><given-names>AN</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Rusinova</surname><given-names>E</given-names></name><name><surname>Gerona-Nevarro</surname><given-names>G</given-names></name><name><surname>Moshkina</surname><given-names>N</given-names></name><name><surname>Joshua</surname><given-names>J</given-names></name><name><surname>Chuang</surname><given-names>PY</given-names></name><name><surname>Ohlmeyer</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>JC</given-names></name><name><surname>Zhou</surname><given-names>MM</given-names></name></person-group><year>2012</year><article-title>Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>28840</fpage><lpage>28851</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.359505</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Lazar</surname><given-names>Z</given-names></name><name><surname>Spector</surname><given-names>DL</given-names></name></person-group><year>2011</year><article-title>Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation</article-title><source>Nature Cell Biology</source><volume>13</volume><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1038/ncb2341</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Bradner</surname><given-names>J</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>LF</given-names></name></person-group><year>2014</year><article-title>Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA</article-title><source>Oncogene</source><volume>33</volume><fpage>2395</fpage><lpage>2404</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.179</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Rappaport</surname><given-names>AR</given-names></name><name><surname>Herrmann</surname><given-names>H</given-names></name><name><surname>Sison</surname><given-names>EA</given-names></name><name><surname>Magoon</surname><given-names>D</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Blatt</surname><given-names>K</given-names></name><name><surname>Wunderlich</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Johns</surname><given-names>C</given-names></name><name><surname>Chicas</surname><given-names>A</given-names></name><name><surname>Mulloy</surname><given-names>JC</given-names></name><name><surname>Kogan</surname><given-names>SC</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name></person-group><year>2011</year><article-title>RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nature10334</pub-id></element-citation></ref></ref-list></back></article>